PDX INSIGHTS
PIONEERING CANCER RESEARCH
Breast Collection
Filter Data:
Institution:
Privacy:
Patient/PDX:



Collection Summaries:





Collection Details:
Search All Columns:
Patient Biomarkers at DiagnosisPDX Biomarkers
Model IDPatient IDPathology Diagnosis
ERPRHER2ERPRHER2Germline BRCA1 StatusGermline BRCA2 StatusPath. Stage
Grade
Clinical Event Pt
Age at Diagnosis
Race
Treatment NaivePatient Treatment
BCM-000224452Infiltrating ductal carcinomaNegativeNegativeNegativeWild TypeWild TypeDistant Metastasis43.62Black or African AmericanNoAnastrozole,Capecitabine,Carboplatin,Docetaxel,Doxorubicin,Gemcitabine,Letrozole,Paclitaxel,Tamoxifen
BCM-00462219Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeWild TypeWild TypeIIBPrimary53.44Hispanic or LatinoNoCyclophosphamide,Docetaxel,Epirubicin
BCM-010424561Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeNot ReportedNot ReportedIIIBG3 (Poorly Differentiated)Primary58.11WhiteNoPaclitaxel
BCM-01134661Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeWild TypeWild TypeIIICG3 (Poorly Differentiated)Distant Metastasis63.34UnknownNoCapecitabine,Carboplatin,Cyclophosphamide,Docetaxel,Doxorubicin,Ixabepilone,Paclitaxel
BCM-013228918Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeWild TypeWild TypeG3 (Poorly Differentiated)Primary58.88Black or African AmericanYesCapecitabine,Carboplatin,Cyclophosphamide,Docetaxel,Doxorubicin,Paclitaxel
BCM-1500314310Adenoid cystic carcinoma (8200/3)NegativeNegativeNegativeNot ReportedNot ReportedIAPrimary66.33Hispanic or LatinoYesCyclophosphamide,Docetaxel
BCM-1500613611+Adenocarcinoma, metastatic, NOS (8140/6)NegativeNegativeNegativeWild TypeWild TypeG3 (Poorly Differentiated)Primary33.91WhiteNoCapecitabine,Carboplatin,Cisplatin,Cyclophosphamide,Doxorubicin,Eribulin,Paclitaxel
BCM-1500825272Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeNot ReportedNot ReportedG3 (Poorly Differentiated)Distant Metastasis63.92WhiteNoCisplatin,Cyclophosphamide,Docetaxel,Doxorubicin,Gemcitabine
BCM-1502932158Infiltrating duct carcinoma, NOS (8500/3)NegativeNegativeNegativeWild TypeWild TypeIAG3 (Poorly Differentiated)Second Primary46.87White,Hispanic or LatinoNoCarboplatin,Cyclophosphamide,Docetaxel,Doxorubicin
BCM-1503032323Infiltrating ductal carcinomaPositivePositiveNegativeWild TypeWild TypeDistant Metastasis34.23WhiteNoAbemaciclib,Anastrozole,Capecitabine,Cyclophosphamide,Doxorubicin,Eribulin,Everolimus,Exemestane,Experimental Drugs,Fluorouracil,Fulvestrant,Goserelin,High-dose estrogen,Letrozole,Megestrol acetate,Other,Paclitaxel,Palbociclib,Tamoxifen
BCM-1503433355Infiltrating duct carcinoma, NOS (8500/3)PositivePositivePositiveWild TypeWild TypeUnknownG3 (Poorly Differentiated)Metastasis62.84WhiteNoAnastrozole,Capecitabine,Docetaxel,Eribulin,Everolimus,Exemestane,Letrozole,Paclitaxel,Palbociclib,Pertuzumab,Trastuzumab
BCM-1504613611+Adenocarcinoma, metastatic, NOS (8140/6)NegativeNegativeNegativeWild TypeWild TypeG3 (Poorly Differentiated)Distant Metastasis33.91WhiteNoCapecitabine,Carboplatin,Cisplatin,Cyclophosphamide,Doxorubicin,Eribulin,Paclitaxel
BCM-1505135624Carcinoma, NOS (8010/3)NegativeNegativeNegativeNot ReportedNot ReportedIIIBPrimary59.38WhiteNoCapecitabine,Carboplatin,Cyclophosphamide,Doxorubicin,Paclitaxel
BCM-1505736302Infiltrating duct carcinoma, NOS (8500/3)PositivePositiveNegativeNot ReportedNot ReportedIIIAG3 (Poorly Differentiated)Primary80.03Hispanic or LatinoNoAnastrozole,Exemestane,Paclitaxel
BCM-1510024590Infiltrating ductal carcinoma, NOSPositivePositiveNegativeWild TypeWild TypeDistant Metastasis37.97WhiteNoAbemaciclib,Capecitabine,Carboplatin,Cyclophosphamide,Denosumab,Docetaxel,Doxorubicin,Eribulin,Fulvestrant,Letrozole,Leuprolide,Paclitaxel,Palbociclib,Stereotactic radiosurgery,Tamoxifen


* indicates the model is private.
+ indicates the patient has multiple models.